Immunotherapies such as PD/PD-L and CTLA-4 inhibitors can reduce the production of insulin from islet cells as in type 1 diabetes mellitus, whereas targeted treatments such as PI3K/mTOR inhibitors can induce insulin resistance similar to that seen in type 2 diabetes mellitus [6,72]. Here, CTLA4 is linked to diabetes mellitus.